PB125 Supplement Boosts Vascular Function in Older Adults by Over 60%
A placebo-controlled trial finds two weeks of PB125 supplementation dramatically improves artery dilation and protects vascular health during bed rest in older adults.
Summary
A randomized, double-blind, placebo-controlled study published in Free Radical Biology and Medicine tested PB125, a botanical Nrf2 activator, in 44 adults split into younger and older groups. After two weeks of supplementation, older adults showed roughly 65% improvement in brachial artery flow-mediated dilation and 57% improvement in popliteal artery dilation — key measures of vascular health. PB125 also protected blood vessel function during five days of bed rest and limb immobilization, and preserved circulating superoxide dismutase levels. Researchers believe PB125 works by activating the Nrf2 pathway, which boosts the body's antioxidant defenses and supports endothelial function, suggesting a practical supplement strategy for maintaining vascular health with aging.
Detailed Summary
Declining vascular function is one of the most consistent features of aging and a major driver of cardiovascular disease and reduced physical capacity. Endothelial dysfunction — the impaired ability of blood vessels to dilate properly — often accelerates in older adults, particularly during periods of physical inactivity. A new randomized, double-blind, placebo-controlled trial from Pathways Bioscience, published in Free Radical Biology and Medicine, tests whether their botanical supplement PB125 can counter these changes.
The study enrolled 20 younger adults and 24 older adults. After just two weeks of PB125 supplementation, older adults experienced approximately 65% improvement in brachial artery flow-mediated dilation and about 57% improvement in popliteal artery flow-mediated dilation — both standard clinical measures of endothelial health. These are substantial gains for a short supplementation window, particularly in an older population.
The trial also examined vascular responses to enforced inactivity, a common aging-related challenge. PB125 preserved brachial and popliteal artery flow-mediated dilation and maintained leg vascular conductance during five days of bed rest in older participants. In younger participants, the supplement protected lower-limb endothelial function during limb immobilization. PB125 also preserved circulating superoxide dismutase, a key antioxidant enzyme, during bed rest.
The proposed mechanism centers on Nrf2, a transcription factor that governs the body's antioxidant and cytoprotective gene expression. PB125 is formulated as a targeted botanical Nrf2 activator, and researchers argue these results provide human evidence that activating this pathway can meaningfully support vascular health in aging populations.
Caveats remain. The study is small at 44 participants and appears to be industry-funded, which introduces potential bias. Longer-term outcomes — whether endothelial improvements translate to reduced cardiovascular events — are not yet established. Independent replication will be essential before strong clinical recommendations can follow.
Key Findings
- Two weeks of PB125 increased brachial artery flow-mediated dilation by ~65% in older adults.
- Popliteal artery dilation improved ~57% in older adults after two weeks of supplementation.
- PB125 preserved vascular conductance in older adults during five days of bed rest.
- Younger adults' lower-limb endothelial function was protected during limb immobilization.
- Circulating superoxide dismutase levels were maintained during bed rest with PB125 use.
Methodology
This is a news report summarizing a randomized, double-blind, placebo-controlled trial published in Free Radical Biology and Medicine, a peer-reviewed journal with solid credibility. The study is small (n=44) and appears to be industry-sponsored by Pathways Bioscience, which warrants scrutiny of potential bias.
Study Limitations
The sample size of 44 participants limits statistical power and generalizability. Industry sponsorship by Pathways Bioscience raises conflict-of-interest concerns that could influence reported outcomes. Long-term cardiovascular endpoints and safety data beyond the two-week window are not reported and should be verified in the primary publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: